Exploratory Grants in Cancer Control (R21 Clinical Trial Optional)

US · MD · Bethesda National Institutes of Health (NIH) grant open #PA-25-253

Response due Sep 07, 2028 · 00:00 UTC

Summary

The National Institutes of Health (NIH) is offering exploratory research grants in the area of cancer control under the R21 mechanism. This program announcement (PA-25-253) supports early-stage, high-risk/high-reward research in cancer control and prevention. Clinical trials are optional under this funding opportunity. The opportunity is open for an extended multi-year window from November 2024 through September 2028.

What they want

Technical requirements

Clinical trial component is optional (not required)
R21 exploratory/developmental research grant mechanism applies
Must align with cancer control research objectives

How they evaluate

Submission: Grants.gov federal grants portal (electronic submission)

Risks & flags

Minimal scope detail provided in synopsis — full program announcement (PA-25-253) on Grants.gov/NIH should be reviewed for complete eligibility, budget caps, and page limits specific to R21 mechanism

Market context

inferred from NAICS

Professional, Scientific & Technical Services

NAICS 541711

US market size: $2.0T
Typical award: $25K – $50M

Typical buyers

All federal civilianDoDStates

Commonly required

8(a)WOSBSDVOSBPE/PMP

Sector-level estimate — full code lookup not yet in catalog.

Exploratory Grants in Cancer Control (R21 …

Due Sep 07

Onboard ↗